Amplia Therapeutics Limited (INNMF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Amplia Therapeutics Limited (INNMF) trades at $0.11 with AI Score 48/100 (Grade C). Amplia Therapeutics Limited is an Australian clinical-stage drug development company focused on focal adhesion kinase (FAK) inhibitors for cancer and fibrosis. Market cap: $56.46M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for INNMF: INNMF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates INNMF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
INNMF: the 1 perspectives are evenly split.
How is this calculated? →Amplia Therapeutics Limited (INNMF) Healthcare & Pipeline Overview
Amplia Therapeutics Limited, based in Australia, is a clinical-stage biotech firm developing FAK inhibitors like Narmafotinib (AMP945) for cancer and fibrosis, currently in Phase 1b/2a trials for pancreatic cancer, positioning them in a competitive landscape focused on novel oncology and fibrosis treatments.
What Is the Investment Thesis for INNMF?
Amplia Therapeutics Limited presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's primary value driver is the successful clinical development and commercialization of Narmafotinib (AMP945), its lead FAK inhibitor. Positive Phase 1b/2a trial results for pancreatic cancer, expected by late 2026, could significantly increase the company's valuation. Further potential lies in expanding Narmafotinib's application to idiopathic pulmonary fibrosis and ovarian cancer, as well as advancing AMP886. However, the company's negative profit margin of -158.5% and negative ROE of -28.5% highlight its reliance on future funding and clinical trial success. The current market capitalization of $56.46M reflects the early stage of development and associated risks. Investors should carefully consider the inherent uncertainties of clinical trials and regulatory approvals in the biotech industry.
Based on FMP financials and quantitative analysis
INNMF Key Highlights
- Market Cap of $56.46M reflects its status as a clinical-stage biotech company.
- Gross Margin of 94.1% indicates strong potential profitability upon successful commercialization of its drug candidates.
- Profit Margin of -158.5% highlights the company's current reliance on R&D spending and lack of revenue generation.
- Debt/Equity Ratio of 0.89 suggests a moderate level of financial leverage.
- Free Cash Flow of $-0.00B indicates the company is currently burning cash to fund its operations and clinical trials.
Who Are INNMF's Competitors?
INNMF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| LLY Eli Lilly and Company | $1202.56 | -0.94% | $1.13T | 98 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 83 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are INNMF's Key Strengths?
- Novel FAK inhibitor technology with potential for multiple indications.
- Lead product (Narmafotinib) in Phase 1b/2a clinical trials.
- Experienced management team with expertise in drug development.
- Strong intellectual property portfolio.
What Are INNMF's Weaknesses?
- Limited financial resources as a clinical-stage company.
- High dependence on the success of clinical trials.
- Lack of commercial infrastructure.
- Negative profitability and cash flow.
What Could Drive INNMF Stock Higher?
- Phase 1b/2a clinical trial results for Narmafotinib in pancreatic cancer expected by late 2026.
- Commencement of clinical trials for Narmafotinib in Idiopathic Pulmonary Fibrosis (IPF) planned for 2027.
- Preclinical development of AMP886 for oncology and fibrosis indications.
- Exploration of strategic partnerships and licensing agreements.
- Potential expansion into new geographic markets (US, Europe) contingent on clinical trial success.
What Are the Key Risks for INNMF?
- Negative return on equity (-18.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays for Narmafotinib and AMP886.
- Competition from other pharmaceutical companies developing similar therapies.
- Regulatory hurdles and changing healthcare policies affecting drug approval and reimbursement.
- Dependence on raising capital to fund operations and clinical trials.
- Limited liquidity and price volatility associated with OTCQB listing.
What Are the Growth Opportunities for INNMF?
- Narmafotinib (AMP945) for Pancreatic Cancer: The Phase 1b/2a clinical trial for Narmafotinib in pancreatic cancer represents a significant growth opportunity. The global pancreatic cancer therapeutics market is projected to reach $3.5 billion by 2028. Positive trial results could lead to accelerated regulatory approval and market entry, providing substantial revenue potential for Amplia Therapeutics. The trial's progress is expected to be a key driver in the near term, with data readouts anticipated by late 2026.
- Expansion into Idiopathic Pulmonary Fibrosis (IPF): Amplia is exploring Narmafotinib's potential in treating IPF, a chronic and progressive lung disease. The global IPF market is estimated at $4.1 billion and is expected to grow. Success in this indication would diversify Amplia's pipeline and address a significant unmet medical need. Clinical trials for IPF are planned to commence in 2027, offering a mid-term growth catalyst.
- Development of AMP886 for Oncology and Fibrosis: AMP886, Amplia's second FAK inhibitor, offers another growth avenue. Its application in oncology and chronic fibrosis indications expands the company's therapeutic reach. Preclinical studies are ongoing, with potential for clinical trials to start in 2028. This provides a longer-term growth opportunity, contingent on successful preclinical development.
- Strategic Partnerships and Licensing Agreements: Amplia can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. Licensing agreements could provide upfront payments, milestone payments, and royalties, boosting revenue and reducing financial risk. Potential partnerships are actively being explored, with the goal of securing a major collaboration by 2027.
- Expansion into New Geographic Markets: While currently focused on Australia, Amplia can expand its clinical trials and commercialization efforts into other geographic markets, such as the United States and Europe. These markets offer larger patient populations and greater revenue potential. Expansion plans are contingent on clinical trial success and regulatory approvals, with initial steps potentially beginning in 2028.
What Opportunities Does INNMF Have?
- Positive clinical trial results leading to regulatory approval.
- Expansion into new indications and geographic markets.
- Strategic partnerships and licensing agreements.
- Advancement of AMP886 into clinical development.
What Threats Does INNMF Face?
- Clinical trial failures or delays.
- Competition from other pharmaceutical companies.
- Regulatory hurdles and changing healthcare policies.
- Difficulty in raising capital to fund operations.
What Are INNMF's Competitive Advantages?
- Patent protection for their FAK inhibitor compounds.
- Proprietary knowledge and expertise in FAK biology and drug development.
- Clinical trial data demonstrating the safety and efficacy of their drug candidates.
- First-mover advantage in developing specific FAK inhibitors for certain indications.
What Does INNMF Do?
Amplia Therapeutics Limited, formerly known as Innate Immunotherapeutics Limited, was founded in 2000 and is headquartered in Melbourne, Australia. The company is dedicated to developing new therapies for cancer and fibrosis, focusing on focal adhesion kinase (FAK) inhibitors. Their lead product, Narmafotinib (AMP945), is an inhibitor of FAK and is currently undergoing a Phase 1b/2a clinical trial for pancreatic cancer. Additionally, Amplia is exploring Narmafotinib's potential in treating idiopathic pulmonary fibrosis and ovarian cancer. The company also has AMP886 in development for oncology and chronic fibrosis indications. Amplia's strategic focus is on addressing unmet medical needs in oncology and fibrotic diseases by targeting FAK, a key regulator of cell growth, survival, and migration. By inhibiting FAK, Amplia aims to disrupt the tumor microenvironment and prevent fibrosis progression, offering new treatment options for patients with limited therapeutic alternatives. The company changed its name to Amplia Therapeutics Limited in September 2018, reflecting its evolved focus on developing a broader range of therapeutic candidates.
What Products and Services Does INNMF Offer?
- Develop focal adhesion kinase (FAK) inhibitors for cancer and fibrosis.
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
- Focus on unmet medical needs in oncology and fibrotic diseases.
- Advance Narmafotinib (AMP945) through clinical development for pancreatic cancer, IPF, and ovarian cancer.
- Develop AMP886 for application in oncology and chronic fibrosis indications.
- Seek strategic partnerships to accelerate drug development and commercialization.
How Does INNMF Make Money?
- Develop and patent novel FAK inhibitors.
- Conduct preclinical and clinical trials to demonstrate safety and efficacy.
- Out-license or partner with larger pharmaceutical companies for commercialization.
- Generate revenue through milestone payments, royalties, and potential direct sales.
What Industry Does INNMF Operate In?
Amplia Therapeutics operates within the highly competitive biotechnology industry, which is characterized by intense research and development, stringent regulatory requirements, and high levels of risk. The market for cancer and fibrosis treatments is substantial, with significant unmet medical needs driving innovation. Amplia's focus on FAK inhibitors positions it within a growing area of interest, as FAK plays a crucial role in tumor growth and fibrosis. The company competes with larger pharmaceutical companies and other biotech firms developing therapies for similar indications. Success in this industry hinges on clinical trial outcomes, regulatory approvals, and effective commercialization strategies.
Who Are INNMF's Key Customers?
- Pharmaceutical companies seeking to in-license novel drug candidates.
- Patients with cancer and fibrotic diseases who may benefit from new therapies.
- Healthcare providers who prescribe and administer these therapies.
- Research institutions and collaborators involved in clinical trials.
FY2026 estForward Outlook
Wall Street analysts project Amplia Therapeutics Limited revenue of about $0 for fiscal 2026, with EPS near $-0.02.
F-Score 1/9Financial Health
Amplia Therapeutics Limited's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 20.11 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE -19%Key Financial Metrics
Return on equity for Amplia Therapeutics Limited stands at -18.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -18.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -11.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 19.78 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -10.0%, the inverse of the P/E and a quick read on earnings relative to price.
Amplia Therapeutics Limited (INNMF) Valuation Context
Valued at $56.46M, INNMF is classified as a micro-cap stock. Relative to its peer group, INNMF's quantitative score of 48/100 is below the peer average of 83/100.
Company Profile
Amplia Therapeutics Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Melbourne, AU. The company is led by CEO Christopher J. Burns. INNMF has traded publicly since 2021.
INNMF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Novel FAK inhibitor technology with potential for multiple indications.
- Lead product (Narmafotinib) in Phase 1b/2a clinical trials.
- Experienced management team with expertise in drug development.
- Strong intellectual property portfolio.
Bear Case
- Limited financial resources as a clinical-stage company.
- High dependence on the success of clinical trials.
- Lack of commercial infrastructure.
- Negative profitability and cash flow.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
INNMF Latest News
-
INNMF Advancing Cancer Treatments
Yahoo! Finance: INNMF News · Jun 5, 2026
-
Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
globenewswire.com · May 19, 2026
-
Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
globenewswire.com · May 8, 2026
INNMF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INNMF.
Price Targets
Wall Street price target analysis for INNMF.
INNMF MoonshotScore
What does this score mean?
The MoonshotScore rates INNMF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
INNMF Advancing Cancer Treatments
Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
INNMF OTC Market Information
The OTCQB Venture Market is the middle tier of the over-the-counter (OTC) market for U.S. companies. It is distinguished from the Pink Open Market by requiring companies to be current in their reporting and undergo an annual verification process. While it offers less stringent listing requirements than major exchanges like the NYSE or NASDAQ, OTCQB provides greater transparency and credibility compared to the lowest OTC tier, potentially attracting a broader range of investors and improving liquidity. Companies on OTCQB are typically earlier-stage or smaller companies seeking to build a track record before pursuing a listing on a national exchange.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity compared to major exchanges.
- Less stringent listing requirements may indicate higher risk.
- Potential for wider bid-ask spreads and price volatility.
- Information asymmetry due to less analyst coverage.
- Higher risk of fraud or manipulation compared to listed companies.
- Verify the company's financial statements and SEC filings.
- Research the management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and bid-ask spreads.
- Consult with a financial advisor before investing.
- Confirm the company's 'Current' disclosure status on OTC Markets.
- OTCQB Venture Market listing indicates a higher level of compliance than the Pink Market.
- Current financial disclosures provide transparency.
- The company has a clear business model and product pipeline.
- Independent directors on the board can provide oversight.
- The company has a website and investor relations presence.
Common Questions About INNMF (Healthcare)
What does Amplia Therapeutics Limited do?
Amplia Therapeutics Limited is a clinical-stage biotechnology company focused on developing novel therapies for cancer and fibrotic diseases. Their primary focus is on focal adhesion kinase (FAK) inhibitors, with their lead product, Narmafotinib (AMP945), currently in Phase 1b/2a clinical trials for pancreatic cancer. The company aims to address unmet medical needs by targeting FAK, a key regulator of cell growth, survival, and migration. They also have a second FAK inhibitor, AMP886, in preclinical development for oncology and chronic fibrosis indications. Amplia's business model involves developing and patenting novel FAK inhibitors, conducting clinical trials, and seeking partnerships for commercialization.
What do analysts say about INNMF stock?
As of March 16, 2026, there is limited analyst coverage specifically for INNMF stock due to its OTCQB listing and clinical-stage nature. However, the biotechnology sector as a whole is closely monitored by analysts, with valuations heavily influenced by clinical trial results, regulatory milestones, and market potential. Key metrics to consider include the company's cash runway, burn rate, and the probability of success for its clinical programs. Investors should conduct their own due diligence and consider the inherent risks associated with investing in early-stage biotech companies before making any investment decisions. The company's progress with Narmafotinib will be a key factor in future analyst assessments.
What are the main risks for INNMF?
The main risks for Amplia Therapeutics Limited include the inherent uncertainties of clinical trials, potential regulatory hurdles, and the need to secure additional funding to support its operations. Clinical trial failures or delays could significantly impact the company's valuation and future prospects. Competition from other pharmaceutical companies developing similar therapies also poses a threat. Additionally, the company's OTCQB listing carries risks associated with limited liquidity and price volatility. Investors should carefully consider these risks before investing in INNMF.
What are the key factors to evaluate for INNMF?
Amplia Therapeutics Limited (INNMF) holds an AI score of 48/100 (low). Not financial advice.
How frequently does INNMF data refresh on this page?
INNMF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven INNMF's recent stock price performance?
Amplia Therapeutics Limited (INNMF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel FAK inhibitor technology with potential for multiple indications. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider INNMF overvalued or undervalued right now?
Valuing Amplia Therapeutics Limited (INNMF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying INNMF?
Before investing in Amplia Therapeutics Limited (INNMF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company filings and press releases as of 2026-03-16.
- AI analysis pending may provide further insights in the future.